These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26471467)

  • 21. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
    J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.
    Narang AK; Trieu J; Radwan N; Ram A; Robertson SP; He P; Gergis C; Griffith E; Singh H; DeWeese TA; Honig S; Annadanam A; Greco S; DeVille C; McNutt T; DeWeese TL; Song DY; Tran PT
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):203-209. PubMed ID: 28094250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 1989 patterns of care study for prostate cancer: five-year outcomes.
    Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
    Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer.
    Ritter MA; Gilchrist KW; Voytovich M; Chappell RJ; Verhoven BM
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):574-80. PubMed ID: 12062599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
    Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K
    Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
    Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of race on biochemical disease recurrence after prostate brachytherapy.
    Yamoah K; Stone N; Stock R
    Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
    Feng FY; Qian Y; Stenmark MH; Halverson S; Blas K; Vance S; Sandler HM; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e361-7. PubMed ID: 21820250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
    Lazarev S; Thompson MR; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased DAB2IP gene expression, which could be induced by fractionated irradiation, is associated with resistance to γ‑rays and α‑particles in prostate cancer cells.
    Yang C; He H; Zhang T; Chen Y; Kong Z
    Mol Med Rep; 2016 Jul; 14(1):567-73. PubMed ID: 27177018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
    Jain S; Lyons CA; Walker SM; McQuaid S; Hynes SO; Mitchell DM; Pang B; Logan GE; McCavigan AM; O'Rourke D; McArt DG; McDade SS; Mills IG; Prise KM; Knight LA; Steele CJ; Medlow PW; Berge V; Katz B; Loblaw DA; Harkin DP; James JA; O'Sullivan JM; Kennedy RD; Waugh DJ
    Ann Oncol; 2018 Jan; 29(1):215-222. PubMed ID: 29045551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
    Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
    Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.